40
Participants
Start Date
October 31, 2001
Primary Completion Date
August 31, 2002
Karenitecin (BNP1350)
Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
For Information call 210-614-1701 for a site near you, Durham
Lead Sponsor
Collaborators (1)
Crown Bioscience
INDUSTRY
BioNumerik Pharmaceuticals, Inc.
INDUSTRY